59-Year-Old Man Presents With Low Back Pain & Bone Lesion

Poll

A 59-year-old man presents with lower back pain. Diagnostic imaging reveals the presence of a lesion in the bone in the lower back area. A prostate and bone biopsy are performed. What is your diagnosis?

A 59-year-old man presents with lower back pain.  Diagnostic imaging reveals the presence of a lesion in the bone in the lower back area.  A prostate and bone biopsy are performed and results are shown below, respectively.


 

What is your diagnosis?

A. Benign prostatic hyperplasia and metastatic adenocarcinoma of lung to bone
B. Prostatic adenocarcinoma metastatic to bone
C. Prostatic adenocarcinoma and metastatic adenocarcinoma to bone of unknown origin
D. Prostatic adenocarcinoma and bone negative for tumor
Related Videos
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Related Content
Findings from the phase 3 CARTITUDE-4 trial support the European approval of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

European Commission Approves Cilta-cel in R/R Multiple Myeloma

April 24th 2024
Article

Findings from the phase 3 CARTITUDE-4 trial support the European approval of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers | Image Credit: © freshidea - stock.adobe.com.

Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers

April 24th 2024
Article

The FDA has set a Prescription Drug User Fee Act date of August 23, 2024, for dostarlimab in all types of primary advanced endometrial cancer.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

April 15th 2024
Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.

FDA Approves Tovorafenib for Relapsed/Refractory Low-Grade Glioma

April 23rd 2024
Article

The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.

Investigators of the phase 3 ALINA trial report no unexpected safety findings with alectinib in ALK-positive non–small cell lung cancer.

Alectinib Significantly Improves DFS Vs Chemo in Resected ALK+ NSCLC

April 23rd 2024
Article

Investigators of the phase 3 ALINA trial report no unexpected safety findings with alectinib in ALK-positive non–small cell lung cancer.